Japan Authorizes Shionogi's JN.1-Adapted COVID-19 Booster Vaccine

Shionogi & Co., Ltd. has received regulatory approval in Japan for its COVGOZE® (JN.1-adapted) recombinant protein COVID-19 vaccine to be used as a booster dose. This authorization addresses the evolving SARS-CoV-2 virus, providing an updated option for public health efforts against current variants. The approval expands the vaccine's utility in the ongoing pandemic response.